Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2018 Dec 8. doi: 10.1007/s00277-018-3570-8. [Epub ahead of print]

2.

Recommendations for the diagnosis and treatment of patients with polycythaemia vera.

Hatalova A, Schwarz J, Gotic M, Penka M, Hrubisko M, Kusec R, Egyed M, Griesshammer M, Podolak-Dawidziak M, Hellmann A, Klymenko S, Niculescu-Mizil E, Petrides PE, Grosicki S, Sever M, Cantoni N, Thiele J, Wolf D, Gisslinger H.

Eur J Haematol. 2018 Jul 30. doi: 10.1111/ejh.13156. [Epub ahead of print]

PMID:
30058088
3.

L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients.

Bello E, Kerry J, Singh S, Yip BH, Kušec R, Killick S, Raynaud S, Boultwood J, Pellagatti A.

Haematologica. 2018 Nov;103(11):e496-e500. doi: 10.3324/haematol.2018.190447. Epub 2018 Jun 14. No abstract available.

4.

Combining information on C reactive protein and serum albumin into the Glasgow Prognostic Score strongly discriminates survival of myelofibrosis patients.

Lucijanic M, Cicic D, Stoos-Veic T, Pejsa V, Rahelic D, Lucijanic T, Vasilj T, Ivic M, Sedinic M, Kusec R.

Blood Cells Mol Dis. 2018 Sep;72:14-16. doi: 10.1016/j.bcmd.2018.06.001. Epub 2018 Jun 6. No abstract available.

PMID:
29891442
5.

Elevated Neutrophil-to-Lymphocyte-ratio and Platelet-to-Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?

Lucijanic M, Cicic D, Stoos-Veic T, Pejsa V, Lucijanic J, Fazlic Dzankic A, Vlasac Glasnovic J, Soric E, Skelin M, Kusec R.

Anticancer Res. 2018 May;38(5):3157-3163.

PMID:
29715157
6.

Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis.

Lucijanic M, Livun A, Tupek KM, Stoos-Veic T, Pejsa V, Kusec R.

Ann Hematol. 2018 Jul;97(7):1293-1294. doi: 10.1007/s00277-018-3294-9. Epub 2018 Mar 12. No abstract available.

PMID:
29532161
7.

Neck adipose tissue - tying ties in metabolic disorders.

Pandzic Jaksic V, Grizelj D, Livun A, Boscic D, Ajduk M, Kusec R, Jaksic O.

Horm Mol Biol Clin Investig. 2018 Feb 9;33(2). pii: /j/hmbci.2018.33.issue-2/hmbci-2017-0075/hmbci-2017-0075.xml. doi: 10.1515/hmbci-2017-0075. Review.

PMID:
29425108
8.

Prognostic implications of low transferrin saturation in patients with primary myelofibrosis.

Lucijanic M, Prka Z, Pejsa V, Stoos-Veic T, Lucijanic J, Kusec R.

Leuk Res. 2018 Mar;66:89-95. doi: 10.1016/j.leukres.2018.01.017. Epub 2018 Feb 3.

PMID:
29407589
9.

Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis.

Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R.

Wien Klin Wochenschr. 2018 Feb;130(3-4):126-133. doi: 10.1007/s00508-018-1318-z. Epub 2018 Jan 25.

PMID:
29372410
10.

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.

Lucijanic M, Mitrovic Z, Cicic D, Prka Z, Pejsa V, Livun A, Stoos-Veic T, Romic Z, Zivkovic M, Lucijanic I, Fabris Z, Kusec R.

Int J Hematol. 2018 Feb;107(2):166-172. doi: 10.1007/s12185-017-2348-4. Epub 2017 Oct 11.

PMID:
29022201
11.

High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis.

Lucijanic M, Livun A, Stoos-Veic T, Pejsa V, Jaksic O, Cicic D, Lucijanic J, Romic Z, Orehovec B, Aralica G, Miletic M, Kusec R.

Hematology. 2018 May;23(4):201-207. doi: 10.1080/10245332.2017.1376843. Epub 2017 Sep 14.

PMID:
28906207
12.

Heat shock protein 27 (HSP27/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival.

Lucijanic M, Livun A, Tupek KM, Stoos-Veic T, Aralica G, Gecek I, Pejsa V, Kusec R.

Leuk Lymphoma. 2017 Oct;58(10):2497-2500. doi: 10.1080/10428194.2017.1296146. Epub 2017 Feb 28. No abstract available.

PMID:
28278711
13.

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.

Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, Ajduković R, Kušec R.

Croat Med J. 2017 Feb 28;58(1):40-48.

14.

Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.

Lucijanic M, Livun A, Tomasovic-Loncaric C, Stoos-Veic T, Pejsa V, Jaksic O, Prka Z, Kusec R.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):523-526. doi: 10.1016/j.clml.2016.06.004. Epub 2016 Jun 8.

PMID:
27381374
15.

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E, Steeples V, Roy S, Scifo L, Armstrong RN, Shaw J, Yip BH, Killick S, Kušec R, Taylor S, Mills KI, Savage KI, Smith CW, Boultwood J.

Leukemia. 2016 Dec;30(12):2322-2331. doi: 10.1038/leu.2016.149. Epub 2016 May 23.

16.

The Degree of Anisocytosis Predicts Survival in Patients with Primary Myelofibrosis.

Lucijanic M, Pejsa V, Jaksic O, Mitrovic Z, Tomasovic-Loncaric C, Stoos-Veic T, Prka Z, Pirsic M, Haris V, Vasilj T, Kusec R.

Acta Haematol. 2016;136(2):98-100. doi: 10.1159/000445247. Epub 2016 May 18. No abstract available.

PMID:
27189016
17.

Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome.

Lucijanić M, Pejša V, Mitrović Z, Štoos-Veić T, Livun A, Jakšić O, Vasilj T, Piršić M, Hariš V, Prka Ž, Kušec R.

Hematology. 2016 Apr;21(3):170-4. doi: 10.1080/10245332.2015.1101964. Epub 2016 Mar 30.

PMID:
27077775
18.

Subtypes and clinical significance of common bile duct varices in portal vein thrombosis: diagnosis and follow-up by Doppler US and EUS.

Grgurevic I, Kujundzic M, Banic M, Kusec R, Bokun T, Vukelic-Markovic M, Bogdanovic Z, Lukic A, Tsochatzis E, Brkljacic B.

Abdom Radiol (NY). 2016 Mar;41(3):476-84. doi: 10.1007/s00261-015-0596-4.

PMID:
27039318
19.
20.

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.

Lucijanic M, Lasan-Trcic R, Kusec R, Pejsa V, Stoos-Veic T, Jaksic O.

Ann Hematol. 2015 Sep;94(9):1617-9. doi: 10.1007/s00277-015-2428-6. Epub 2015 Jun 20. No abstract available.

PMID:
26088813
21.

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).

Bello E, Pellagatti A, Shaw J, Mecucci C, Kušec R, Killick S, Giagounidis A, Raynaud S, Calasanz MJ, Fenaux P, Boultwood J.

Br J Haematol. 2015 Oct;171(2):210-214. doi: 10.1111/bjh.13563. Epub 2015 Jun 18.

22.

Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome.

Lucijanić M, Pejša V, Mitrović Z, Štoos-Veić T, Livun A, Jakšić O, Vasilj T, Piršić M, Hariš V, Prka Ž, Kušec R.

Hematology. 2015 May 4. [Epub ahead of print]

PMID:
25938278
23.

Endoscopic ultrasound guided fine needle aspiration and useful ancillary methods.

Tadic M, Stoos-Veic T, Kusec R.

World J Gastroenterol. 2014 Oct 21;20(39):14292-300. doi: 10.3748/wjg.v20.i39.14292. Review.

24.

[The use of peripherally inserted central catheter (PICC) in patients with hematological malignancies--a single center experience].

Mitrović Z, Komljenović I, Jaksic O, Prka Z, Crnek SS, Stojsavljević RA, Pirsic M, Haris V, Kusec R, Dautovic D, Pejsa V.

Lijec Vjesn. 2014 May-Jun;136(5-6):136-40. Croatian.

PMID:
25154182
25.

The relationship between methylenetetrahydrofolate reductase C677T gene polymorphism and diabetic nephropathy in Croatian type 2 diabetic patients.

Tomić NG, Marusić S, Bozikov V, Kusec R, Bacić-Vrca V, Tadić M.

Coll Antropol. 2013 Sep;37(3):789-93.

PMID:
24308218
26.

Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.

Zivko M, Kusec R, Galesić K.

Coll Antropol. 2013 Sep;37(3):765-70.

PMID:
24308214
27.

Bone morphogenetic proteins regulate differentiation of human promyelocytic leukemia cells.

Topić I, Ikić M, Ivčević S, Kovačić N, Marušić A, Kušec R, Grčević D.

Leuk Res. 2013 Jun;37(6):705-12. doi: 10.1016/j.leukres.2013.03.002. Epub 2013 Mar 23.

PMID:
23528261
28.

Diffuse skin hyperpigmentation in CD30+ lymphoproliferation.

Prka Z, Tomasovic-Loncaric C, Pejsa V, Nevajda B, Kusec R.

Ann Saudi Med. 2012 May-Jun;32(3):318-20. doi: 10.5144/0256-4947.2012.318.

29.

Lifestyle habits and the risk of head and neck cancer in Zagreb region.

Znaor A, Virag M, Znaor T, Manojlović S, Kusec R.

Coll Antropol. 2011 Dec;35(4):1125-8.

PMID:
22397248
30.

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.

Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH.

Biol Direct. 2011 May 18;6:23. doi: 10.1186/1745-6150-6-23.

31.

[Diagnosis and therapy for patients with essential thrombocythemia. Guidelines of Croatian Cooperative Group for hematologic disorders--KROHEM].

Labar B, Kusec R, Jaksić B, Skare-Librenjak L, Nacinović-Duletić A, Petricević-Sincić J, Carzavec D, Coha B, Gverić-Krecak V, Corović E, Lang N, Lojen-Nemet Z, Babok-Flegarić R; Croatian Cooperative Group for hematologic disorders.

Lijec Vjesn. 2010 Nov-Dec;132(11-12):333-9. Croatian.

PMID:
21294321
32.

Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.

Stoos-Veić T, Livun A, Ajduković R, Pejsa V, Jaksić O, Kusec R.

Coll Antropol. 2010 Jun;34(2):425-9.

PMID:
20698113
33.

Cytogenetics of multiple myeloma.

Trcić RL, Skelin IK, Sustercić D, Planinc-Peraica A, Ajduković R, Haris V, Kusec R, Begović D.

Coll Antropol. 2010 Mar;34(1):41-4.

PMID:
20432732
34.

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.

Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang L, Clark RE, Wainscoat JS.

Leukemia. 2010 Jun;24(6):1139-45. doi: 10.1038/leu.2010.65. Epub 2010 Apr 22.

PMID:
20410925
35.

Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells.

Campbell AJ, Lyne L, Brown PJ, Launchbury RJ, Bignone P, Chi J, Roncador G, Lawrie CH, Gatter KC, Kusec R, Banham AH.

Br J Haematol. 2010 Apr;149(2):221-30. doi: 10.1111/j.1365-2141.2009.08070.x. Epub 2010 Jan 20.

PMID:
20096010
36.

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR.

Blood. 2010 Apr 8;115(14):2891-900. doi: 10.1182/blood-2009-08-236596. Epub 2009 Dec 11.

37.

Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes.

Grcević D, Kusec R, Kovacić N, Lukić A, Lukić IK, Ivcević S, Nemet D, Seiwerth RS, Ostojić SK, Croucher PI, Marusić A.

Leuk Res. 2010 Jun;34(6):742-51. doi: 10.1016/j.leukres.2009.10.016. Epub 2009 Nov 18.

PMID:
19926132
38.

V(D)J targeting mistakes occur at low frequency in acute lymphoblastic leukemia.

Vanura K, Vrsalovic MM, Le T, Marculescu R, Kusec R, Jäger U, Nadel B.

Genes Chromosomes Cancer. 2009 Aug;48(8):725-36. doi: 10.1002/gcc.20677.

PMID:
19455608
39.

[Single cell--definitive diagnosis! Where the profession ends and the art begins?].

Kardum-Skelin I, Fabijanić I, Jelić-Puskarić B, Siftar Z, Kardum Paro MM, Trcić RL, Mahovlić V, Kusec R, Seili-Bekafigo I.

Acta Med Croatica. 2008 Oct;62(4):343-9. Croatian.

PMID:
19205411
40.

[European Working Group Consensus--EUMET criteria for clinico-hematologic response in primary chronic myelofibrosis].

Kusec R.

Lijec Vjesn. 2007 May;129 Suppl 3:14-5. Croatian. No abstract available.

PMID:
18959053
41.
42.

The JAK2V617F mutation: no impact on circulating hematopoietic progenitors in myeloproliferative disorders.

Wappl M, Jaeger E, Kusec R, Schwarzinger I, Geissler K, Oehler L.

Ann Hematol. 2008 Jun;87(6):509-11. doi: 10.1007/s00277-007-0428-x. Epub 2008 Jan 5. No abstract available.

PMID:
18180923
43.

Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status.

Vrsalovic MM, Pejsa V, Veic TS, Kolonic SO, Ajdukovic R, Haris V, Jaksic O, Kusec R.

Cancer Biol Ther. 2007 Sep;6(9):1434-6. Epub 2007 Jun 13.

PMID:
17873518
44.

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdilès MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR.

Blood. 2006 Nov 15;108(10):3548-55. Epub 2006 Jul 27.

45.

More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

Kusec R, Jaksic O, Ostojic S, Kardum-Skelin I, Vrhovac R, Jaksic B.

Blood. 2006 Jul 1;108(1):405-6; author reply 406. No abstract available.

46.

Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics.

Kolonić SO, Dzebro S, Kusec R, Planinc-Peraica A, Dominis M, Jaksić B.

Int J Hematol. 2006 May;83(4):331-6.

PMID:
16757434
47.

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.

Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J.

Leukemia. 2006 Apr;20(4):671-9.

PMID:
16498395
48.
49.

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT.

Blood. 2006 Mar 1;107(5):2098-100. Epub 2005 Nov 17.

Supplemental Content

Support Center